Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Plos Pathogens|March 24, 2015
An 18 kDa scaffold protein is critical for Staphylococcus epidermidis biofilm formationRahel Decker, Christoph Burdelski, Melanie Zobiak, et al.
Endocrine Connections|November 19, 2017
Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumoursLogan Mills, Panagiotis Drymousis, Yogesh Vashist, et al.
International Journal of Cancer|September 19, 2015
Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancersChristoph Burdelski, Sandra Kleinhans, Martina Kluth, et al.
Oncotarget|April 1, 2015
HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomyCristina Villares Zabalza, Meike Adam, Christoph Burdelski, et al.
Oncotarget|March 13, 2015
Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancerChristoph Burdelski, Christian Strauss, Maria Christina Tsourlakis, et al.
Plos One|June 2, 2015
Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate CancersChristoph Burdelski, Erzen Bujupi, Maria Christina Tsourlakis, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 23, 2016
p16 upregulation is linked to poor prognosis in ERG negative prostate cancerChristoph Burdelski, Tatsiana Dieckmann, Asmus Heumann, et al.
Experimental and Molecular Pathology|March 22, 2015
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancerChristoph Burdelski, Oliver M Ruge, Nathaniel Melling, et al.
Scientific Reports|May 19, 2017
Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancerAsmus Heumann, Özge Kaya, Christoph Burdelski, et al.
The Lancet. Respiratory Medicine|December 13, 2021
Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trialMahir Karakas, Ibrahim Akin, Christoph Burdelski, et al.
Pageof 5